Preparation and in vitro Studies of [125-I]IUDR-T101 Antibody Conjugate

Published

January 1, 2000

Author(s)

M C. Chakrabarti, C H. Paik, J A. Carrasquillo

Abstract

Idoxuridine labeled with ¹²⁵I was conjugated to polylysine. This conjugate was then coupled to the carbohydrate side chains of T101 monoclonal antibodiy (anti-CD5). The immunoreactivity, cell retention, cytotoxicity, and intracellular localization of this conjugate was tested in CCRF-CEM cells (CD5 positive). The conjugate had 68 % immunoreactivity. The retention of ¹²⁵I by CCRF-CEM cells was higher for the conjugate than for T101 directly labeled with ¹²⁵I and more of it localized in the nucleus than did the ¹²⁵I-labeled T101. The ¹²⁵I IUDR-polylysine-T101 conjugate was more cytotoxic than the ¹²⁵I-labeled T101. In conclusion, the conjugation of [¹²⁵I]IUDR to T101 is feasible, and preferential targeting of the ¹²⁵I to the nucleus is obtained.

Citation

Cancer Biotherapy and Radiopharmaceuticals

Volume

14

Issue

No. 2

Pub Type

Journals

Keywords

CD5, endocytosis, iodine, IUDR, monoclonal antibody

Citation

Chakrabarti, M. , Paik, C. and Carrasquillo, J. (2000), Preparation and in vitro Studies of [¹²⁵-I]IUDR-T101 Antibody Conjugate, Cancer Biotherapy and Radiopharmaceuticals (Accessed December 5, 2023)